title: Pharmacokinetics and pharmacodynamics of lanoteplase (n-PA).
abstract: In acute myocardial infarction rapid, complete, and sustained reperfusion of the infarct-related coronary artery is the most important therapeutic principle. Lanoteplase or n-PA, a third-generation plasminogen activator consisting of a deletion and point mutant of tissue-type plasminogen activator (t-PA), is a promising agent to approach this therapeutic goal. The molecule exhibits an increased plasma half-life allowing single-bolus administration. In this article, after characterizing the n-PA molecule, the currently available pharmacokinetic and pharmacodynamic data including the results of the InTIME study are reviewed.
authors.affiliation: Abteilung Kardiologie, Medizinische Klinik und Poliklinik, Universität Freiburg, Germany.
authors.forename: T K
authors.initials: TK
authors.lastname: Nordt
authors.forename: M
authors.initials: M
authors.lastname: Moser
authors.forename: B
authors.initials: B
authors.lastname: Kohler
authors.forename: W
authors.initials: W
authors.lastname: Kübler
authors.forename: C
authors.initials: C
authors.lastname: Bode
mesh_terms: D000818:Animals; D005343:Fibrinolytic Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000503:physiopathology; D010959:Tissue Plasminogen Activator / Q000493:pharmacokinetics* / Q000627:therapeutic use
chemical_list: D005343:Fibrinolytic Agents; C081981:lanoteplase; D010959:Tissue Plasminogen Activator